Biomarkers identified for prostate cancer patients through genome-scale screening

作者：Lei‐Yun Wang, Jiajia Cui, Tao Zhu, Weihua Shao, Yi Zhao, Sai Wang, Yupeng Zhang, Ji-Chu Wu, Le Zhang · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.20739 · 被引用次数：22 · 研究领域：Molecular Biology Techniques and Applications、Cancer-related molecular mechanisms research、RNA Research and Splicing

// Lei-Yun Wang 1, 2 , Jia-Jia Cui 1, 2 , Tao Zhu 1, 2 , Wei-Hua Shao 1, 2 , Yi Zhao 1, 2 , Sai Wang 3 , Yu-Peng Zhang 3 , Ji-Chu Wu 4 and Le Zhang 3 1 Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha 410008, P.R. China 2 Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P.R. China 3 Department of Neurology, XiangYa Hospital, Central South University, Changsha 410008, P.R. China 4 Department of Cardiovascular, Central Hospital of ShaoYang, ShaoYang 422000, P.R. China Correspondence to: Le Zhang, email: zlzdzlzd@163.com Keywords: prostate cancer, biomarker screening, genome-scale, prognosis, gene expression Received: May 17, 2017      Accepted: August 07, 2017      Published: September 08, 2017 ABSTRACT Prostate cancer is a threat to men and usually occurs in aged males. Though prostate specific antigen level and Gleason score are utilized for evaluation of the prostate cancer in clinic, the biomarkers for this malignancy have not been widely recognized. Furthermore, the outcome varies across individuals receiving comparable treatment regimens and the underlying mechanism is still unclear. We supposed that genetic feature may be responsible for, at least in part, this process and conducted a two-cohort study to compare the genetic difference in tumorous and normal tissues of prostate cancer patients. The Gene Expressi...